<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362069">
  <stage>Registered</stage>
  <submitdate>7/02/2012</submitdate>
  <approvaldate>16/02/2012</approvaldate>
  <actrnumber>ACTRN12612000199819</actrnumber>
  <trial_identification>
    <studytitle>The use of attenuated Botulinium Toxin to prevent long term loss of salivary secretion in patients undergoing radiation of the head &amp; neck for malignancies</studytitle>
    <scientifictitle>The use of attenuated Botulinium Toxin to prevent long term loss of salivary secretion in patients undergoing radiation of the head &amp; neck for malignancies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Xerostomia (dry mouth) post bilateral irradation of salivary glands in the field of radiotherapy.</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Head and neck</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single dose of attenuated botulinum toxin (100units), delivered directly via subcutanous injection into the parotid gland through the skin. 3-4 days prior to radiation treatment</interventions>
    <comparator>All patients who receive bilateral neck irradiation</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Any salivary gland function (patient questionairre)</outcome>
      <timepoint>3 months post radiation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical assesment including a sheet assessing patient's subjective perception of symptoms, and also a clinician's objective assessment.</outcome>
      <timepoint>3 months post radiation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>&gt;20 years old. Existing head and neck cancer. Radiation as the primary treatment modality. Bilateral submandibular irradiation</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No preexisting salivary gland disease</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Patient seen at the Head and Neck OPD are advised that they are eligible. They receive an appointment with the Radiation Oncologist to assess suitability.</concealment>
    <sequence>Patients will be identified and their results recorded at each appointment</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/05/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NT</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Darwin Hospital</primarysponsorname>
    <primarysponsoraddress>PO BOX 41326
Casuarina NT 0811</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Royal Darwin Hospital</fundingname>
      <fundingaddress>PO BOX 41326
Casuarina NT 0811</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is looking at the use of attenuated Botulinium Toxin to prevent long term loss of salivary secretion in patients undergoing radiation of the head &amp; neck for malignancies. Botulinium Toxin is used to protect the parotid gland, responsible for 60% of resting saliva, from irradiation, and will be administered via a subcutaneous injection of the attenuated botulinum toxin delivered directly into the parotid gland through the skin. This will cause the gland to slow down, and therefore avoid becoming the target of irradiation. Xerostomia (or dry mouth) is a dehabilitating condition which is inevitable in bilateral neck irradiation for the treatment of head and neck cancers Trial Details In this study you will receive a single dose of attenuated botulinum toxin (100units), delivered via subcutaneous injection directly into the parotid gland through the skin 3-4 days prior to your scheduled radiation treatment. Who is it for? This study is available for participants 20 years and over who are undergoing radiation as the primary treatment modality, and have bilateral submandibular irradiation with existing head and neck cancer</summary>
    <trialwebsite>Nil</trialwebsite>
    <publication>Nil yet</publication>
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Menzies School of Health Research</ethicname>
      <ethicaddress>PO Box 41096
Casuarina NT0811</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>21/03/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Eileen TAN-GORE</name>
      <address>Royal Darwin Hospital
PO Box 41326
Casuarina NT 0811</address>
      <phone>61 08 8922 8888</phone>
      <fax />
      <email>Eileen.Tan-Gore@nt.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Eileen TAN-GORE</name>
      <address>Royal Darwin Hospital
PO Box 41326
Casuarina NT 0811</address>
      <phone>61 08 8922 8888</phone>
      <fax />
      <email>Eileen.Tan-Gore@nt.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Eileen TAN-GORE</name>
      <address>Royal Darwin Hospital
PO Box 41326
Casuarina NT 0811</address>
      <phone>61 08 8922 8888</phone>
      <fax />
      <email>Eileen.Tan-Gore@nt.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>